Affimed to Present Immune Cell Engager Data at ASCO Annual Meeting and EACR-AACR-SIC Special Conference
Affimed N.V. (AFMD)
Last affimed n.v. earnings: 11/19 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
affimed.com/investor-relations.php
Company Research
Source: GlobeNewswire
Heidelberg, Germany, May 17, 2017 - Affimed N.V. (Nasdaq: AFMD), a clinical stage biopharmaceutical company focused on discovering and developing highly targeted cancer immunotherapies, announced today that data for Affimed's preclinical AFM24 and AFM26 programs will be presented at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting being held June 2 - 6, 2017 in Chicago, IL and at the EACR-AACR-SIC Special Conference 2017 being held June 24 - 27, 2017 in Florence, Italy, respectively. ASCO 2017 Annual Meeting AFM26 (poster)Abstract: AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma (#8045)Poster: Monday, June 5, 2017 8:00 AM-11:30 AM CST, Session Hematologic Malignancies AFM24 (abstract only)Abstract: EGFR/CD16A tetravalent bispecific antibody AFM24 to engage NK-cells to kill EGFR expressing tumor cells and safety results in cynomolgus monkey studies. (#e14001)Online Publica
Show less
Read more
Impact Snapshot
Event Time:
AFMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AFMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AFMD alerts
High impacting Affimed N.V. news events
Weekly update
A roundup of the hottest topics
AFMD
News
- Affimed Reports 2023 Financial Results and Operational ProgressGlobeNewswire
- Affimed To Report Full Year 2023 Financial Results & Corporate Update on March 28, 2024GlobeNewswire
- Affimed Announces 1-for-10 Reverse Stock SplitGlobeNewswire
- Affimed Provides Clinical Response Update on AFM24-102 Trial in EGFR-wildtype Non-Small Cell Lung CancerGlobeNewswire
- Affimed Announces Leadership Change and Organizational RestructuringGlobeNewswire
AFMD
Earnings
- 11/14/23 - Beat
AFMD
Sec Filings
- 3/28/24 - Form 6-K
- 3/28/24 - Form 20-F
- 3/11/24 - Form 6-K
- AFMD's page on the SEC website